MimiVax Reports Positive Interim Results in SurVaxM Trial
February 15, 2025
The clinical trial is designed to evaluate the safety, efficacy, and overall benefit of SurVaxM in patients with newly diagnosed glioblastoma who receive standard-of-care treatment